Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period

Trial Profile

Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Liraglutide (Primary) ; Orlistat
  • Indications Glucose intolerance; Obesity
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 May 2016 Results of a post hoc dose-proportionality assessment (n=331) published in the Clinical Pharmacokinetics.
    • 11 Jul 2010 Results of the 84-week extension trial were presented at the 11th International Congress on Obesity.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top